報價延遲最少15分鐘:2024/12/24 13:09 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.868 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.10/-1.38
|
|
企業價值
32.30M
|
| 資產負債 |
|
每股賬面淨值
2.70
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 13:09 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease. |